Brief: Elicera Q3 Operating Loss Widens To SEK 6.8 Mln
Nov 18 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* Q3 OPERATING LOSS TOTALED SEK -6,753,799 (-216,550).
* Q3 LOSS FOR PERIOD TOTALED SEK -6,753,799 (-211,132)
* Q3 CASH FLOW FROM OPERATING ACTIVITIES TOTALED SEK
-13,418,888
(-104,589)
Source text for Eikon: ID:nWkr6HgJgJ
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application